Coherus Oncology
CompanyUnited StatesFounded 2010
Coherus Oncology develops 8 assets, the furthest approved (Cimerli in diabetic macular edema). Mostly antibody acting on IL27, CCR8 and PDCD1; based in the United States, founded in 2010.
- 8
- Assets
- Furthest stage
- Approved
- Raised
- $119M
- 13
- Trials
- 14
- Signals
Pipeline
8Neutralizes VEGF-A to inhibit abnormal blood vessel growth and vascular leakage.
Approved, Antibody, diabetic macular edema, diabetic retinopathy
Blocks PD-1 to restore T-cell immune responses against cancer cells.
Approved, Antibody, PDCD1, nasopharyngeal carcinoma, esophageal squamous cell carcinoma
Neutralizes TNF to reduce inflammatory signaling.
Approved, Antibody, Active Rheumatoid Arthritis, ankylosing spondylitis
5 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
12 assets
In the full profile
- Evidence behind the mechanisms5
- Trials22
- Funding rounds and grants4
- Deals20
- People24
- Signals17
- Similar companies6